A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study Of Arn-509 In Men With Non-Metastatic (M0) Castration-Resistant Prostate
Posted Date: May 15, 2019
- Investigator: Robert Franklin
- Type of Study: Drug
The main purpose of this research study is to determine whether ARN-509 is safe and effective when compared to placebo (inactive substance) in delaying the development of metastases in prostate cancer patients with rising PSA.
Criteria:
To Be Eligible For The Study You Must Have Prostate Cancer That Is At High Risk Of Progressing And S
Keywords:
Arn-509-003, Cancer, Castration-Resistant, Non-Metastatic , Prostate
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu